Tosilizumab

Tosilizumab
Antibodi monoklonal
JenisWhole antibody
SumberTemplat:Infobox drug/mab source
TargetReseptor IL-6
Data klinis
Nama dagangActemra, Roactemra
Biosimilartocilizumab-aazg,[1][2] tocilizumab-bavi,[3][4] Tofidence,[3][4][5][6][7] Tyenne[1][8]
AHFS/Drugs.commonograph
MedlinePlusa611004
License data
Kategori
kehamilan
Rute
pemberian		Intravena, subkutan
Kode ATC
Status hukum
Status hukum
Data farmakokinetika
Waktu paruh eliminasi8–14 hari selama kondisi stabil (tergantung pada konsentrasi)
Pengenal
Nomor CAS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
Data sifat kimia dan fisik
RumusC6428H9976N1720O2018S42
Massa molar144.987,06 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Tosilizumab, dijual dengan nama merek Actemra, adalah sebuah obat imunosupresif, yang dipakai untuk pengobatan artritis reumatoid dan artritis idiopatik remaja sistemik, sebuah bentuk artritis berat pada anak-anak. Tocilizumab dikembangkan bersama oleh Universitas Osaka dan Chugai, dan dilisensikan pada 2003 oleh Hoffmann-La Roche.[17]

Tocilizumab diberikan pengaturan pemakaian darurat untuk pengobatan COVID-19 di Amerika Serikat pada Juni 2021.[18]

Referensi

  1. ^ a b "Tyenne- tocilizumab-aazg injection, solution, concentrate". DailyMed. 6 March 2024. Diarsipkan dari versi aslinya tanggal 25 April 2024. Diakses tanggal 25 April 2024.
  2. ^ "Tyenne- tocilizumab-aazg injection, solution". DailyMed. 22 May 2024. Diakses tanggal 28 November 2024.
  3. ^ a b "Tofidence- tocilizumab injection". DailyMed. 27 March 2024. Diakses tanggal 16 June 2024.
  4. ^ a b "FDA approves first biosimilar to Actemra to treat adult and pediatric arthritis". U.S. Food and Drug Administration (FDA) (Press release). 29 September 2023. Diarsipkan dari versi aslinya tanggal 25 February 2024. Diakses tanggal 6 March 2024.
  5. ^ "FDA Approves Biogen's Tofidence (tocilizumab-bavi), a Biosimilar Referencing Actemra" (Press release). Biogen Inc. 29 September 2023. Diarsipkan dari versi aslinya tanggal 30 September 2023. Diakses tanggal 1 October 2023 – via GlobeNewswire.
  6. ^ a b Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama Tofidence EPAR
  7. ^ Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama Tofidence PI
  8. ^ a b "Tyenne EPAR". European Medicines Agency. 2 October 2023. Diarsipkan dari versi aslinya tanggal 5 October 2023. Diakses tanggal 5 October 2023.
  9. ^ a b "Australian Product Information Actemra (tocilizumab)" (PDF). MedAdvisor International. 2 September 2022. Diarsipkan dari versi aslinya tanggal 1 October 2023. Diakses tanggal 19 April 2023.
  10. ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Diarsipkan dari versi aslinya tanggal 31 March 2024. Diakses tanggal 31 March 2024.
  11. ^ "Actemra". COVID-19 vaccines and treatments portal. 13 October 2022. Diarsipkan dari versi aslinya tanggal 5 December 2022. Diakses tanggal 29 October 2022.
  12. ^ "Actemra- tocilizumab injection, solution, concentrate Actemra- tocilizumab injection, solution Actemra ACTPen- tocilizumab injection, solution". DailyMed. Diarsipkan dari versi aslinya tanggal 7 June 2021. Diakses tanggal 24 June 2021.
  13. ^ Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama FDA EUA
  14. ^ Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama Roactemra EPAR
  15. ^ "Tyenne Product information". Union Register of medicinal products. 18 September 2023. Diarsipkan dari versi aslinya tanggal 1 October 2023. Diakses tanggal 1 October 2023.
  16. ^ "COVID-19 medicines". European Medicines Agency (EMA). 14 October 2024. Diakses tanggal 14 October 2024.
  17. ^ Markus Harwart (2008). "Die Entwicklung von Tocilizumab" [The development of tocilizumab] (dalam bahasa Jerman). Krankenpflege-Journal. Diarsipkan dari asli tanggal 2018-10-15. Diakses tanggal 2016-04-30.
  18. ^ Kesalahan pengutipan: Tanda <ref> tidak sah; tidak ditemukan teks untuk ref bernama FDA COVID PR

Pranala luar

  • Nomor uji klinis NCT00109408 for "A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis" di ClinicalTrials.gov
  • Nomor uji klinis NCT00106535 for "A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)" di ClinicalTrials.gov
  • Nomor uji klinis NCT00106548 for "A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis" di ClinicalTrials.gov
  • Nomor uji klinis NCT00106574 for "A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis" di ClinicalTrials.gov
  • Nomor uji klinis NCT00106522 for "A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy" di ClinicalTrials.gov
  • Nomor uji klinis NCT01331837 for "A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors" di ClinicalTrials.gov
  • Nomor uji klinis NCT00988221 for "A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis" di ClinicalTrials.gov
  • Nomor uji klinis NCT00642460 for "A Study of Roactemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)" di ClinicalTrials.gov


Ikon rintisan

Artikel bertopik farmasi ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.
Kembali kehalaman sebelumnya